Oncology Nursing Society Annual Progress Report: 2008 Formula Grant



Similar documents
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey

Disclosure. I have the following relationships with commercial interests:

The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer

Karen B. Hirschman, PhD MSW Research Assistant Professor School of Nursing. Geriatric Grand Rounds Friday, December 9, 2011 TRANSITIONS

Screening for psychological distress in inoperable lung cancer patients: an evaluation of the Brief Distress Thermometer (BDT)

Developing a model for peer support for patients with lung cancer. Final Report May 2008

Best Practices in Patient Navigation and Cancer Survivorship Survey Results

Care Guide: Cancer Distress Management

Impact of Breast Cancer Genetic Testing on Insurance Issues

The Effectiveness of an Outpatient Interdisciplinary Team in Reducing Distress with Lung Cancer Patients

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

Running Head: INTERNET USE IN A COLLEGE SAMPLE. TITLE: Internet Use and Associated Risks in a College Sample

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

Ann Hablitzel, RN, BSN, MBA Hospice Care of California

Canines and Childhood Cancer

SYNOPSIS. Risperidone: Clinical Study Report CR003274

Recommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality

Identifying and Prioritizing Research Gaps. Tim Carey, M.D., M.P.H. Amica Yon, Pharm.D. Chris Beadles, M.D. Roberta Wines, M.P.H.

First Experiences with an Internet based Program for Maintenance Treatment of Patients with Eating Disorders

Pragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost. Mei Lu, PhD Christine Joseph, Ph.D

Understanding the Pain Trajectory During Treadmill Testing in Peripheral Artery Disease

WHODAS 2.0 World Health Organization Disability Assessment Schedule item version, self-administered

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care

Hospice Care It s About How You Live

Effect of Anxiety or Depression on Cancer Screening among Hispanic Immigrants

Oncology Competency- Pain, Palliative Care, and Hospice Care

Running head: ASPERGER S AND SCHIZOID 1. A New Measure to Differentiate the Autism Spectrum from Schizoid Personality Disorder

#3: SAMPLE CONSENT FORM

Treating Depression to Remission in the Primary Care Setting. James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health

Breast cancer treatment for elderly women: a systematic review

CRITICALLY APPRAISED PAPER (CAP)

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

Clinical Trials Need More Subjects

Population Percent C.I. All Hennepin County adults aged 18 and older 11.9% ± 1.1

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Learning Disabilities

Das Trajekt-Modell 1. The Trajectory Model

A PUBLICATION OF THE NATIONAL COUNCIL FOR ADOPTION ADOPTION USA: SUMMARY AND HIGHLIGHTS OF A CHARTBOOK ON THE NATIONAL SURVEY OF ADOPTIVE PARENTS

MaineCare Value Based Purchasing Initiative

Simplifying the measurement of co-morbidities and their influence on chemotherapy toxicity

Ask Us About Clinical Trials

Service delivery interventions

Lisa R. Fortuna, MD, MPH Michelle V. Porche, Ed. D Sripallavi Morampudi, MBBS Stanley Rosenberg, PhD Douglas Ziedonis, MD, MPH

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH (603)

Measure #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care

Transitional Grant Area (TGA) Definition

The Obama Administration s Record on Supporting the Nursing Workforce

Clinical Trials: Questions and Answers

BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION

Friday, May 2. Clinical Trials: Is Your Staff Competent? Session 10:15 11:45 am Ballroom C

EDUCATING, SUPPORTING & COORDINATING CARE: ONCOLOGY NURSE NAVIGATORS

Kaiser Permanente Southern California Depression Care Program

Susan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer. Judith A. Salerno, M.D., M.S. President and Chief Executive Officer

Preventive Medicine and the Need for Routine Hearing Screening in Adults

Care Programme Approach (CPA)

Prepared by:jane Healey ( 4 th year undergraduate occupational therapy student, University of Western Sydney

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

Diabetes Prevention in Latinos

SPECIALTY CASE MANAGEMENT

A Descriptive Study of Depression, Substance Abuse, and Intimate Partner Violence Among Pregnant Women

Almost 12 million Americans to date are living

Lost in Translation: The use of in-person interpretation vs. telephone interpretation services in the clinic setting with Spanish speaking patients

Palliative Nursing. An EssEntiAl REsouRcE for HospicE And palliative nurses

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)

CRITICALLY APPRAISED PAPER (CAP)

Ch HOSPICE SERVICES 55 CHAPTER HOSPICE SERVICES GENERAL PROVISIONS RECIPIENT ELIGIBILITY AND DURATION OF COVERAGE

Clinical Spotlight in Breast Cancer

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Twin Cities Healthy Start Pregnancy Psychosocial Risk Screening Validation Study

Ethnic Minorities, Refugees and Migrant Communities: physical activity and health

Critical Appraisal of Article on Therapy

Case-control studies. Alfredo Morabia

Transcription:

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for the grant award period January 1, 2009 through June 30, 2012. Accomplishments for the reporting period are described below. Research Project 1: Project Title and Purpose The SEA Preparatory Intervention for Women with Metastatic Breast Cancer - The purpose of this pilot randomized controlled project is to provide information to women newly diagnosed with metastatic breast cancer (MBC) that they can use at diagnosis and across the illness continuum to maintain quality of life and reduce distress. Duration of Project 1/1/2009-6/30/2012 Project Overview Aims 1) To determine the feasibility (recruitment, attrition, acceptability) of the use of an anticipatory guidance intervention Support, Education and Advocacy (SEA) Intervention in women newly diagnosed with MBC. 2) To explore the efficacy of the SEA Intervention on quality of life, physical and emotional distress and symptom distress in women newly diagnosed with MBC over the first six months of illness as compared to care as usual. Results of this study will then be used for development of a larger randomized controlled trial (RCT) to test efficacy of the SEA Intervention. Methods This is a pilot study, non-blinded, repeated-measures randomized controlled trial in women (n=48) from diagnosis of MBC through the first 6 months across the illness continuum. Measures of feasibility and acceptability will be assessed at baseline and at 2 time points (3 and 6 months). Outcomes of emotional distress (The Distress Thermometer and McCorkle Symptom Distress Scale) and quality of life (Functional Assessment of Cancer Therapy) will be assessed. Effect sizes for larger trial will be determined. Oncology Nursing Society - 2008 Formula Grant Page 1

Principal Investigator Margaret Q. Rosenzweig, PhD, CRNP School of Nursing University of Pittsburgh 329-A Victoria Building 3500 Victoria Street Pittsburgh, PA 15261 Other Participating Researchers Robert Arnold, MD, Adam M. Brufsky, MD, PhD employed by the University of Pittsburgh Medical Center Heidi Donovan, PhD, RN, Catherine Bender, PhD, RN, Kathleen Slavish, BA employed by the University of Pittsburgh Expected Research Outcomes and Benefits The SEA Intervention has significant potential to advance the science of oncology nursing. This intervention fills a void in essential patient preparation for a specific disease trajectory. There are many written and electronic resources for women with breast cancer. There are few resources available specifically for women with metastatic breast cancer. This SEA Intervention provides immediate concrete information to women at a time when women need specific information to better adopt coping strategies and problem solving techniques for emotional and physical distress related to metastatic breast cancer. If efficacious, the SEA Intervention can be adopted by oncology nurses and used as a standard teaching intervention at the time of the diagnosis of MBC. It will be different from many other teaching materials incorporated into the cancer clinical setting because it has been developed based on the stated patient experience, respects the similarities and differences among racial and economic backgrounds, evaluated by the patient population intended to serve and will be empirically tested for acceptability and efficacy. The SEA Intervention is designed to be patient driven and specifically tailored to enhance the woman s self care ability. The SEA Intervention includes: a. Support to promote ability to meet evolving emotional needs through identification of available resources; b. Education regarding 1) current treatment and side effects including physical sensations and symptoms to expect 2) temporal characteristics of the illness and symptom experience (when to expect them) 3) environmental features (what one might see and hear during an illness experience) and 4) causes of symptoms, sensations, and experiences; and c. Advocacy skills to enable communication regarding evolving concerns and provide resources for women to request further information and needed referrals. Oncology Nursing Society - 2008 Formula Grant Page 2

Summary of Research Completed Recruitment During the current reporting period, July 1, 2011-June 30, 2012, three subjects were enrolled. Therefore, at the time of this report, a total of 32 patients have been recruited, consented and enrolled in the study. Year 03 was not an ideal recruitment year. The research team experienced a decrease in recruitment attributed in part to lack of subject interest for participation in a research study as well as clinician restriction on patients deemed eligible for recruitment. Reasons for patients not consenting and enrolling in the study after contact and recruitment by a researcher included: 1) not interested in being part of a research study, 2) not wanting to be bothered and 3) fearful of learning information about disease. Reasons for clinician restriction on eligible patients included: 1) age of patient, 2) progression of disease and 3) mental status. While we were optimistic at the end of Year 02 that we would be able to meet our target recruitment goal by the end of reporting Year 03, we were not successful. Recruiting from this unique population at a vulnerable time is challenging. Ideally, subjects would have been recruited on the day of MBC diagnosis. However, few subjects were recruited at the diagnosis of MBC and instead were recruited, enrolled and consented several months after diagnosis due to patient's reluctance to think about advanced disease or clinic staff not allowing recruitment. This cohort represented regional demographics: white (n=26/32, 81%), married (20/32, 63%), completed high school education (32/32, 100%) and all (32/32, 100%) had health insurance. See Table 1. Attrition There has been no attrition due to failure to follow up with participants. There has been attrition due to death in three subjects (SEA=2 and UC=1). These three subjects completed baseline data but were deceased prior to completing time point 2 and time point 3 data. Reason for death for all three subjects included progression of disease. Acceptability All subjects who have completed the acceptability questionnaire (n=13) have rated the intervention as favorable: 12.7± 2.8 (scale=0-16) and as needed information. Aim 2: To explore the efficacy of the SEA Intervention on quality of life, physical and emotional distress and symptom distress in women newly diagnosed with MBC over the first six months of illness as compared to care as usual. The results detailed from this point forward are reflective of all subjects that participated in the research study. While format and presentation of results is similar to last year, the outcome measurements have remained the same and thus this is a reflection of the data of all subjects. 32 subjects have completed baseline data collection, 29 patients completed follow up data at time point 2 and 29 patients completed follow up data at time point 3. The mean scores and standard deviations for the three outcome measures of quality of life (FACT), physical and emotional Oncology Nursing Society - 2008 Formula Grant Page 3

distress (Distress Thermometer) and symptom distress (McCorkle Symptom Distress) are listed in Table 2. Quality of Life Quality of Life is measured using the Functional Assessment of Cancer Therapy (FACT), a validated 33-item general cancer quality-of-life measure for evaluating patients receiving cancer treatment. Scores range from 0-108, with a higher score indicating better quality of life. Table 2 illustrates mean and standard deviation FACT scores for both the Intervention Group and the Usual Care Group. At baseline, the FACT scores for the Intervention group and Usual Care group scores were relatively similar. The mean FACT score for the Intervention group (n=15) was 77.2 (SD=4.5) and the mean score for the Usual Care group (n=17) was 78.9 (SD=3.8). At time point 2, both the Intervention group and the Usual Care group illustrated an increase in mean FACT scores. The Intervention group (n=13) had a mean score of 82.7 (SD=3.4) and the Usual Care group (n=16) had a mean score of 83.3 (SD=3.9) At time point 3, both the Intervention group and the Usual Care group illustrated slightly higher scores from baseline, but no major change from time point 2 mean FACT scores. The Intervention group (n=13) had a mean score of 82.0 (SD=3.0) and the Usual Care group (n=16) had a mean score of 84.5 (SD=4.4). Emotional and Physical Distress Emotional and physical distress is measured using the Distress Thermometer. The Distress Thermometer is a screening tool widely used by health professionals to assess the level of distress that a patient is experiencing in a 0-10 scale. 0 indicates no distress while 10 indicates extreme distress. See Table 2. At baseline, the distress scores for the Intervention group and Usual Care group were relatively similar. The mean distress score for the Intervention group (n=15) was 4.2 (SD=0.8) and the mean score for the Usual Care group (n=17) was 3.5 (SD=0.6). At time point 2, the distress scores for the Intervention group (n=13) decreased slightly from what was recorded at baseline to a mean score of 3.3 (SD=0.9). The mean score for the Usual Care group (n=16) was 3.3 (SD=0.9). At time point 3, the distress scores for the Intervention group (n=13) decreased slightly from what was recorded at baseline and at time point 2 to a mean score of 3.2 (SD=0.8). The mean score for the Usual Care group (n=16) was 2.1 (SD=0.7). Oncology Nursing Society - 2008 Formula Grant Page 4

Symptom Distress The McCorkle Symptom Distress scale has been developed and validated as a cancer-specific tool for assessing symptoms. This 13-item scale measures degree of distress on a 1-5 Likert scale. A total summed score of 25 or above indicates moderate distress; scores of 33 or above indicate severe distress that requires immediate intervention. See Table 2. At baseline, the symptom distress scores for the Intervention group and Usual Care group were relatively similar. The mean symptom distress score for the Intervention group (n=15) was 25.4 (SD=1.8) and the mean score for the Usual Care group (n=17) was 24.2 (SD=1.6). At time point 2, the symptom distress scores for both the Intervention group and the Usual Care group remained relatively unchanged from the recorded baseline scores. The mean score for the Intervention group (n=13) was 24.5 (SD=1.6) and the mean score for the Usual Care group (n=16) was 23.7 (SD=1.8). At time point 3, the symptom distress scores for both the Intervention group and the Usual Care group decreased from baseline and time point 2. The Intervention group (n=13) had a mean score of 22.6 (SD=1.9) and the Usual Care group (n=16) had a mean score of 22.9 (SD=2.1). Conclusion The results at the completion of this project do not suggest that the SEA Intervention had a measurable impact on the quality of life scores, distress scores or symptom distress scores of the subjects randomized to the Intervention arm., time point 2 and time point 3 mean FACT, mean Distress and mean Symptom Distress scores were relatively similar between the SEA Intervention and Usual Care groups. Despite the inability of the SEA Intervention to have a meaningful impact on the quality of life, distress and symptom distress scores as hypothesized, the comments from an open ended survey and Likert-Scale survey assessing the impact of the SEA Intervention s components suggests that the information provided in the intervention is both important and necessary as women receive the news of diagnosis of metastatic breast cancer. The data related to the acceptability of the components of the intervention can be viewed in last year s report, as no new SEA Intervention subjects were accrued during this reporting period. Subjects accrued during this reporting period were randomized to the usual care arm. Oncology Nursing Society - 2008 Formula Grant Page 5

Table 1. Socio-demographic Characteristics of Study Participants Characteristic SEA Intervention Usual Care (n=15) (n=17) Race: White 11(73) 15 (88) Black 4 (27) 2 (12) Age (years) 47.7± 12.3 53.1± 8.6 Education (years) 15.1± 2.5 15.4± 2.7 Marital Status Currently married 9 (60) 11 (65) Other 6 (40) 6 (35) Annual household income: < $30,000 4 (27) 2 (12) $30,000 9 (60) 14 (82) Refused 2 (13) 1 (6) Employment Status: Working full time 4 (27) 5 (29) Working part time 1 (7) 3 (18) Disabled 3 (20) 3 (18) Other 7 (47) 6 (35) MBC diagnosis (median days) 89 139 Oncology Nursing Society - 2008 Formula Grant Page 6

Table 2: Quality of Life, Symptom Distress and Overall Cancer Distress Characteristic Quality of Life (FACT-G) SEA Intervention (n=15) Usual Care (n=17) SEA Intervention (n=13) Usual Care Time point 2 (n=16) SEA Intervention (n=13) Usual Care Time point 3 (n=16) Higher score indicates greater quality of life FACT-G total (0-108) 77.2± 4.5 78.0± 3.8 82.7± 3.4 83.3± 3.9 82.0± 3.0 84.5± 4.4 Subscales Physical (0-28) 19.8±1.7 20.9± 1.0 21.7± 1.4 22.8± 1.2 21.8± 1.0 22.1± 1.6 Social (0-28) 23.2± 1.8 22.2± 1.3 23.4± 0.9 23.3± 1.3 24.2± 0.8 23.9± 1.3 Emotional (0-24 17.5± 1.5 17.4± 1.1 19.0± 1.1 19.6± 0.9 18.0± 1.2 19.9± 0.9 Functional (0-28) 16.6± 1.1 17.4± 1.2 18.6± 1.1 17.6± 1.3 18.1± 0.9 18.6± 1.3 Symptom Distress Higher score indicates greater distress Symptom Distress (5-65) 25.4± 1.8 24.2± 1.6 24.5± 1.6 23.7± 1.8 22.6± 1.9 22.9± 2.1 Overall Cancer Distress Higher score indicates greater overall cancer distress Cancer Distress (0-10) 4.2± 0.8 3.5± 0.6 3.3± 0.9 3.3± 0.7 3.2± 0.8 2.1± 0.7 Oncology Nursing Society - 2008 Formula Grant Page 7